Ventyx Biosciences, Inc.
NASDAQ:VTYX
Overview | Financials
Company Name | Ventyx Biosciences, Inc. |
Symbol | VTYX |
Currency | USD |
Price | 1.84 |
Market Cap | 130,107,633 |
Dividend Yield | 0% |
52-week-range | 1.67 - 11.48 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Raju S. Mohan Ph.D. |
Website | https://www.ventyxbio.com |
An error occurred while fetching data.
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD